GovChime
Notice ID: 2031f91c4d444f2a8949b9f91351b6daCombined Synopsis/Solicitation

Follow-up testing for tumorigenicity and oncogenicity

Archived on September 10, 2024. Original response deadline: . Full description on SAM.gov.

Overview

Response deadline
5:00 PM UTC−04:00
Posted
August 21, 2024
Notice type
Combined Synopsis/Solicitation
NAICS
621511: Medical Laboratories
Agency
Department of Health and Human ServicesCENTERS FOR DISEASE CONTROL AND PREVENTION

Notice details

Office
CDC OFFICE OF ACQUISITION SERVICES
Place of performance
Atlanta, GA, 30341
Last updated
Dec 4, 2025

Identifiers

Solicitation number
75D301-24-Q-78224
Notice ID
2031f91c4d444f2a8949b9f91351b6da

Description

This is a combined synopsis/solicitation for commercial items prepared in accordance with the format in Subpart 12.6, as supplemented with additional information included in this notice. This announcement constitutes the only solicitation; proposals are being requested and a written solicitation will not be issued. The solicitation number for this requirement is 75D301-24-Q-78224 and is hereby issued as a Request for Quote (RFQ). The solicitation document and incorporated provisions and clauses are those in effect through Federal Acquisition Circular FAC 2024-05 dated May 22, 2024. The associated North American Industrial Classification System (NAICS) code for this procurement 621511 Medical Laboratory Testing. This is a RFQ for the procurement of the test of Master Cell Bank (MCB) of Expi293F tm cells in further follow-up testing for tumorigenicity and oncogenicity. The Government intends to award a Firm-Fixed Price (FFP) contract as a result of this solicitation that will include the terms and conditions that are set forth herein. The provision at 52.212-1, Instructions to Offerors-Commercial, applies to this acquisition along with the addenda to the provision included in the solicitation document. FAR 52.212-2, Evaluation-Commercial Items, is included, and the specific evaluation criteria are included in paragraph (a) of that provision. Offerors shall include a completed copy of the provision at 52.212-3, Offeror Representations and Certifications-Commercial Items, with its offer or indicate if it is available online at SAM.gov. FAR 52.212-4, Contract Terms and Conditions-Commercial Items, applies to this acquisition; there are no addenda to the clause. FAR 52.212-5, Contract Terms and Conditions Required To Implement Statutes or Executive Orders-Commercial Items, applies to this acquisition and the additional FAR clauses cited in the clause that are applicable have been noted. There are no additional contract requirement(s) or terms and conditions determined by the contracting officer to be necessary for this acquisition and consistent with customary commercial practices. No telephonic quotes will be processed. All responses must be received no later than the date stated above. Inquiries shall reference the solicitation number75D301-24-Q-78224, on the subject line and be sent to the Contract Specialist, Dawnnia Daley by email at xwf5@cdc.gov

Full description on SAM.gov

Award Overview

No prior contract identified

No prior award matched this notice's agency, NAICS, place of performance and PSC within 18 months. It may be a new requirement.

Contacts

Documents

No documents available.

Lifecycle

Solicitation:75D301-24-Q-78224
  1. Market Research
  2. Combined Synopsis
  1. Market ResearchAug 19, 2024

    Follow-up testing for tumorigenicity and oncogenicity

    Notice fc749f8f635a4c6db4e3363e596d23d3 on SAM.gov

  2. Combined SynopsisCurrentAug 21, 2024

    Follow-up testing for tumorigenicity and oncogenicity

    Notice 2031f91c4d444f2a8949b9f91351b6da on SAM.gov

Similar Opportunities

Title
Match
Phase
Deadline

Additional Details

Solicitation Number

75D301-24-Q-78224

Archive Date

Sep 10, 2024

Office Address

ATLANTA, GA, 30333